<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890772</url>
  </required_header>
  <id_info>
    <org_study_id>1217</org_study_id>
    <nct_id>NCT01890772</nct_id>
  </id_info>
  <brief_title>Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1</brief_title>
  <official_title>A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Morgan, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for people who have been diagnosed with chronic hepatitis C, specifically those&#xD;
      who have a certain type of the virus, genotype 1, and who have not yet received treatment for&#xD;
      hepatitis C. This pilot study is designed to test whether the addition of vitamin D, to the&#xD;
      three drugs (Incivek (telaprevir), Pegasys (peginterferon alfa-2a), and ribavirin) that are&#xD;
      approved by the Food and Drug Administration (FDA) for the treatment of hepatitis C, can help&#xD;
      eliminate the HCV from the body. Currently, doctors are unsure if the addition of vitamin D&#xD;
      to prescribed hepatitis C therapy will have any effects on how the body clears the virus.&#xD;
&#xD;
      Once enrolled, participants will be randomly assigned (like flipping a coin) to receive&#xD;
      telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (treatment group) or telaprevir +&#xD;
      peginterferon alfa-2a + ribavirin (control group). A total of 80 participants, of all&#xD;
      races/ethnicities, will be included in this study, at 5 to 10 VA hospital study sites (10 -&#xD;
      20 participants/site).&#xD;
&#xD;
      Participants assigned to the treatment group will begin a lead-in phase where they will&#xD;
      receive 5,000 IU of vitamin D3 per day. Every two weeks during the lead-in phase,&#xD;
      participants will be tested to determine the Vitamin D level in their blood, as well as other&#xD;
      tests, including HCV RNA (to determine the amount of virus present) and calcium levels. Once&#xD;
      an adequate level of Vitamin D is detected in participants' blood, participants will begin&#xD;
      treatment with telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (15,000 IU/week)&#xD;
      for 12 weeks.&#xD;
&#xD;
      Participants randomized to the control group will immediately begin treatment with telaprevir&#xD;
      + peginterferon alfa-2a + ribavirin for 12 weeks. At the end of Week 12 the participants'&#xD;
      involvement in the study will be complete.&#xD;
&#xD;
      Adverse events and effects of vitamin D3 will be obtained by assessing participants' medical&#xD;
      history, physical examination, and blood tests at clinic visits. HCV RNA will be assessed at&#xD;
      Screening, Day 1, Week 2, 4, 8 and 12.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>4 weeks</time_frame>
    <description>Hepatitis C virus Ribonucleic Acid identifies the presence of Hepatitis C in the blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative record of unanticipated or unintended medical occurrences, not necessarily related to the study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>VitD+telaprevir+peginterferon+ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir + Peginterferon + Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <arm_group_label>Telaprevir + Peginterferon + Ribavirin</arm_group_label>
    <arm_group_label>VitD+telaprevir+peginterferon+ribavirin</arm_group_label>
    <other_name>Incivek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <arm_group_label>Telaprevir + Peginterferon + Ribavirin</arm_group_label>
    <arm_group_label>VitD+telaprevir+peginterferon+ribavirin</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Telaprevir + Peginterferon + Ribavirin</arm_group_label>
    <arm_group_label>VitD+telaprevir+peginterferon+ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>VitD+telaprevir+peginterferon+ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Hepatitis C genotype 1 infection&#xD;
&#xD;
          -  Treatment naïve&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Agree to genetic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease other than from hepatitis C&#xD;
&#xD;
          -  HCV infection with mixed genotypes&#xD;
&#xD;
          -  Decompensated liver disease&#xD;
&#xD;
          -  AFP&gt;100ng/ml.&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Serum 25(OH)D less than 12ng/ml or greater than 30ng/ml&#xD;
&#xD;
          -  Regular vitamin D supplement use&#xD;
&#xD;
          -  Regular calcium supplement use&#xD;
&#xD;
          -  Refusal to abstain from vitamin D supplementation&#xD;
&#xD;
          -  Current or past history of kidney stones&#xD;
&#xD;
          -  Current use of any of the prohibited medications listed in section 5.5 and the&#xD;
             INCIVEK® package insert.&#xD;
&#xD;
          -  Need for therapeutic vitamin D or calcium (e.g. treatment for osteoporosis,&#xD;
             osteomalacia, hyperparathyroidism etc.), in the opinion of the investigator&#xD;
&#xD;
          -  Significant substance abuse within the past 6 months,&#xD;
&#xD;
          -  Suicidal attempt in the past 10 years or suicidal ideation in past 3 months, or any&#xD;
             other psychiatric condition that the investigator deems would make a subject unsuited&#xD;
             for treatment with peginterferon or ribavirin.&#xD;
&#xD;
          -  Confirmed or suspected malignancy, or history of malignancy within the past 3 years&#xD;
             (except treated basal cell carcinoma of the skin or in situ carcinoma of the uterine&#xD;
             cervix)&#xD;
&#xD;
          -  Any autoimmune disease not easily controlled (in the opinion of the investigator)&#xD;
&#xD;
          -  Any condition resulting in malabsorption (&#xD;
&#xD;
          -  Poorly controlled thyroid disorder, or diabetes mellitus (HbA1c &gt; 9)&#xD;
&#xD;
          -  Glomerular diseases (e.g., glomerulosclerosis or glomerulonephritis) associated with a&#xD;
             serum creatinine &gt;1.5 times the upper limit of normal&#xD;
&#xD;
          -  Current or history of any clinically significant cardiac abnormalities/dysfunction&#xD;
             (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension,&#xD;
             complex congenital heart disease, cardiomyopathy, significant arrhythmia) including&#xD;
             current uncontrolled hypertension or history of use of antianginal agents for cardiac&#xD;
             conditions (Inclusion will be considered if clearance by a cardiologist is obtained.)&#xD;
&#xD;
          -  Receipt of an investigational drug within the past 30 days&#xD;
&#xD;
          -  Females who have a positive pregnancy test at the time of screening, are breastfeeding&#xD;
             or who anticipate pregnancy within the next 18 months, or men with pregnant partners&#xD;
&#xD;
          -  Lack of agreement from subject to use two forms of acceptable contraception&#xD;
&#xD;
          -  History or other evidence of any significant illness which, in the opinion of the&#xD;
             investigator, would make the patient, unsuitable for the study&#xD;
&#xD;
          -  Laboratory Exclusions&#xD;
&#xD;
        Hemoglobin: &lt;12gm/dl male or female&#xD;
&#xD;
        Neutrophil: &lt;1,200/mm3&#xD;
&#xD;
        Platelets: &lt;90,000/mm3&#xD;
&#xD;
        INR: &gt;1.5&#xD;
&#xD;
        Albumin: &lt;3.2gm/dl&#xD;
&#xD;
        Total Bilirubin: &gt;2.0mg/dl&#xD;
&#xD;
        HbA1c: &gt;9.5%&#xD;
&#xD;
        Serum Creatinine: &gt;1.5 times the upper limit of normal&#xD;
&#xD;
        Serum Calcium Within local laboratory normal range&#xD;
&#xD;
        Parathyroid hormone (PTH) &lt;10 or &gt;55 pg/mL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Affairs Long Beach Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VAHCS</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2013</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Timothy Morgan, MD</investigator_full_name>
    <investigator_title>Chief, Hepatology</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

